Pituitary Derived-Intermedin is an Estrogen-Modulated Factor for Reducing Blood Pressure
Recruitment status was Recruiting
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
Calcitonin, calcitonin gene-related peptides (CGRPs), adrenomedullin, and amylin belong to a unique group of peptide hormones important for the regulation of calcium balance, neurotransmission, cardiovascular homeostasis, and glucose metabolism. We, the investigators at Chang Gung Memorial Hospital, recently identified intermedin as a novel peptide hormone belonging to this unique peptide ligand family. Adrenomedullin is a 52-amino-acid peptide and is one of the most potent vasodilators. Plasma adrenomedullin is elevated in a variety of pathological conditions such as hypertension, renal failure, heart failure, and septic shock. CGRPα and CGRPβ are 37-amino acid neuropeptides; primarily release from sensory nerves; and play important roles in regulating peripheral vascular tone and controlling blood flow in various organs. Human mature intermedin encodes 40-amino-acid and is expressed mainly in the adrenocorticotrophs of the anterior and intermediate pituitary lobe. Intermedin signals through calcitonin receptor-like receptor (CRLR)/receptor activity-modifying protein (RAMP) receptor complexes, and CRLR/RAMP signaling has been proven to be critical for vascular tone regulation. Based on this finding, we had documented that intraperitoneal administration of intermedin dose-dependently suppressed blood pressure in normal Sprague-Dawley rats. In addition, our preliminary in vitro and in vivo studies demonstrated that ovariectomy lead to a tenfold reduction of intermedin transcript expression in the pituitary in rats whereas subsequent estrogen treatment increased pituitary intermedin expression to a level similar to that of intact rats. Taken together, we propose that pituitary-derived intermedin is regulated by estrogen and exhibits potent hypotensive effects. To address this hypothesis, in Specific Aim 1, we will investigate the regulation of secretion and expression of intermedin in vitro and in vivo using cultured pituitary cells and oophorectomized rats. In Specific Aim 2, we will study the molecular mechanism by which estrogen stimulates intermedin gene expression. In Specific Aim 3, to demonstrate that the estrogen-dependent regulation of intermedin represents a critical link in the regulation of blood pressure in women, we will study the relationship between blood pressure and blood intermedin levels using a cross-sectional study. Our studies will provide a better understanding of the mechanisms by which sex hormones modulate blood pressure and open a new window for postmenopausal hypertension treatment.
| Condition | Intervention |
|---|---|
|
Menopause Hypertension |
Behavioral: intermedin |
| Study Type: | Observational |
| Study Design: | Observational Model: Defined Population Observational Model: Natural History Time Perspective: Cross-Sectional Time Perspective: Prospective |
| Official Title: | Intermedin is an Estrogen- Modulated Factor for Reducing Blood Pressure |
| Estimated Enrollment: | 500 |
| Study Start Date: | May 2005 |
| Estimated Study Completion Date: | May 2007 |
Show Detailed Description
Eligibility| Ages Eligible for Study: | 20 Years to 90 Years |
| Genders Eligible for Study: | Female |
| Accepts Healthy Volunteers: | Yes |
Inclusion Criteria:
- Premenopausal women: no reported change in menstrual cycle pattern
- Early peri-menopausal women: reported change in menstrual cycle frequency in preceding year with a bleed in the preceding 3 months
- Late peri-menopausal women: no menses in the preceding 3-11 months
- Postmenopausal women: no menses in the preceding 12 months
- Patients who received oophorectomy
- Patients who received hysterectomy for benign uterus tumor
- Patients underwent assisted reproductive technology (ART).
Exclusion Criteria:
- Patients underwent chemotherapy or radiotherapy in past two years
Contacts and Locations| Contact: Chailin Chang, M.D. | 886-968372657 | amego@cgmh.org.tw |
| Taiwan | |
| Chailin Chang | Recruiting |
| Kwei-Shan, Tao-Yuan, Taiwan, 333 | |
| Contact: Chialin Chang, M.D. 886-968372657 amego@cgmh.org.tw | |
| Principal Investigator: Chialin Chang, M.D. | |
| Principal Investigator: | Chialin Chang, M.D. | Chang Gung Memorial Hospital, Department of OB/GYN, 5. Fu-Hsing St. Kwei-Shan, Tao-Yuan, Taiwan, ROC |
More Information
Publications:
| ClinicalTrials.gov Identifier: | NCT00133783 History of Changes |
| Other Study ID Numbers: | NMRPG34 |
| Study First Received: | August 23, 2005 |
| Last Updated: | October 25, 2005 |
| Health Authority: | Taiwan: Department of Health |
Keywords provided by Chang Gung Memorial Hospital:
|
Intermedin estradiol female hypertension |
Premenopausal and postmenopausal women Surgically-induced menopause women IVF treatment patients |
Additional relevant MeSH terms:
|
Hypertension Vascular Diseases Cardiovascular Diseases Estrogens Melanocyte-Stimulating Hormones |
Hormones Hormones, Hormone Substitutes, and Hormone Antagonists Physiological Effects of Drugs Pharmacologic Actions |
ClinicalTrials.gov processed this record on May 23, 2013